Alexander R. Marr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexander R. Marr has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Adam S. Kittai
Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
20 shared publications - Alexander He
The Ohio State University 1 Division of Hematology, Department of Internal Medicine Columbus, Ohio
20 shared publications - Andrew D. Mitchell
Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio
20 shared publications - Arnau Peris-Cuesta
Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston, Texas
20 shared publications - Brandi R. Walker
Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio
20 shared publications - Britten K. Gordon
The Ohio State University 1 Division of Hematology, Department of Internal Medicine Columbus, Ohio
20 shared publications
Latest Publications
- Open Access
SNP-Based Chromosomal Microarray Analysis in the Era of Optical Genome Mapping: An Enriched Case-Series Evaluating Copy-Neutral Events
Background/Objectives: Chromosomal microarray analysis (CMA) is an essential tool in modern cytogenetics for detecting copy number alterations and copy-neutral loss of heterozygosity (CN-LOH). As optical genome mapping (OGM) emerges as a potential replacement for traditional cytogenetic methods, the extent to which CMA remains necessary in routine diagnostic workflows remains to be elucidated. Methods: We retrospectively reviewed 53 primary neoplastic cases, selected from a larger cohort of 327 hematologic malignancy specimens, in which CMA identified one or more CN-LOH events. Event size, genomic content, and correlation with next-generation sequencing (NGS) findings were assessed. A separate cohort of newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) was analyzed to evaluate disease-specific CN-LOH frequency. Results: Nearly half of CN-LOH events detected were FLT3, JAK2, TET2, TP53, and RUNX1. Additionally, two-thirds of cases harbored pathogenic or likely pathogenic variants by NGS within the corresponding CN-LOH regions, further underscoring the clinical value of detecting these copy-neutral events. In contrast, CN-LOH was uncommon in B-ALL, and most alterations identified by CMA would be detectable by OGM. Many of these patients also harbored complex structural rearrangements that required multiple conventional assays for full characterization; these could be resolved by OGM in a single analysis. Conclusions: Our findings indicate that although OGM excels at resolving complex structural variants, CMA remains essential for detecting copy-neutral events. Until OGM achieves improved sensitivity for CN-LOH, an integrated approach utilizing conventional cytogenetics, CMA, NGS, and OGM provides the most reliable framework for comprehensive genomic assessment across cancer types.
Open AccessSNP-Based Chromosomal Microarray Analysis in the Era of Optical Genome Mapping: An Enriched Case-Series Evaluating Copy-Neutral Events
Background/Objectives: Chromosomal microarray analysis (CMA) is an essential tool in modern cytogenetics for detecting copy number alterations and copy-neutral loss of heterozygosity (CN-LOH). As optical genome mapping (OGM) emerges as a potential replacement for traditional cytogenetic methods, the extent to which CMA remains necessary in routine diagnostic workflows remains to be elucidated. Methods: We retrospectively reviewed 53 primary neoplastic cases, selected from a larger cohort of 327 hematologic malignancy specimens, in which CMA identified one or more CN-LOH events. Event size, genomic content, and correlation with next-generation sequencing (NGS) findings were assessed. A separate cohort of newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) was analyzed to evaluate disease-specific CN-LOH frequency. Results: Nearly half of CN-LOH events detected were FLT3, JAK2, TET2, TP53, and RUNX1. Additionally, two-thirds of cases harbored pathogenic or likely pathogenic variants by NGS within the corresponding CN-LOH regions, further underscoring the clinical value of detecting these copy-neutral events. In contrast, CN-LOH was uncommon in B-ALL, and most alterations identified by CMA would be detectable by OGM. Many of these patients also harbored complex structural rearrangements that required multiple conventional assays for full characterization; these could be resolved by OGM in a single analysis. Conclusions: Our findings indicate that although OGM excels at resolving complex structural variants, CMA remains essential for detecting copy-neutral events. Until OGM achieves improved sensitivity for CN-LOH, an integrated approach utilizing conventional cytogenetics, CMA, NGS, and OGM provides the most reliable framework for comprehensive genomic assessment across cancer types.
- Open Access
- 8 May 2026
- Published by MDPI AG in Preprints.org
Chromosomal Microarray Analysis in the Era of Optical Genome Mapping: Clinical Implications in Detecting Copy-Neutral Events
Background/Objectives: Chromosomal microarray analysis (CMA) is an essential tool in modern cytogenetics for detecting copy number alterations and copy-neutral loss of heterozygosity (CN-LOH). As optical genome mapping (OGM) emerges as a potential replacement for traditional cytogenetic methods, the extent to which CMA remains necessary in routine diagnostic workflows remains to be elucidated. Methods: We retrospectively reviewed 53 primary neoplastic cases in which CMA identified one or more CN-LOH events. Event size, genomic content, and correlation with next-generation sequencing (NGS) findings were assessed. A separate cohort of newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) was analyzed to evaluate disease-specific CN-LOH frequency. Results: Nearly half of CN-LOH events detected were <25 Mb, below the current detection threshold of OGM. Many encompassed clinically relevant genes, including FLT3, JAK2, TET2, TP53, and RUNX1. Additionally, two-thirds of cases harbored pathogenic or likely pathogenic variants by NGS within the corresponding CN-LOH regions, further underscoring the clinical value of detecting these copy-neutral events. In contrast, CN-LOH was uncommon in B-ALL, and most alterations identified by CMA would be detectable by OGM. Many of these patients also harbored complex structural rearrangements that required multiple conventional assays for full characterization; these could be resolved by OGM in a single analysis. Conclusions: Our findings indicate that although OGM excels at resolving complex structural variants, CMA remains essential for detecting copy-neutral events. Until OGM achieves improved sensitivity for CN-LOH, an integrated approach utilizing conventional cytogenetics, CMA, NGS, and OGM provides the most reliable framework for comprehensive genomic assessment across cancer types.
- 8 May 2026
- Published by MDPI AG in Preprints.org
Open AccessChromosomal Microarray Analysis in the Era of Optical Genome Mapping: Clinical Implications in Detecting Copy-Neutral Events
Background/Objectives: Chromosomal microarray analysis (CMA) is an essential tool in modern cytogenetics for detecting copy number alterations and copy-neutral loss of heterozygosity (CN-LOH). As optical genome mapping (OGM) emerges as a potential replacement for traditional cytogenetic methods, the extent to which CMA remains necessary in routine diagnostic workflows remains to be elucidated. Methods: We retrospectively reviewed 53 primary neoplastic cases in which CMA identified one or more CN-LOH events. Event size, genomic content, and correlation with next-generation sequencing (NGS) findings were assessed. A separate cohort of newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) was analyzed to evaluate disease-specific CN-LOH frequency. Results: Nearly half of CN-LOH events detected were <25 Mb, below the current detection threshold of OGM. Many encompassed clinically relevant genes, including FLT3, JAK2, TET2, TP53, and RUNX1. Additionally, two-thirds of cases harbored pathogenic or likely pathogenic variants by NGS within the corresponding CN-LOH regions, further underscoring the clinical value of detecting these copy-neutral events. In contrast, CN-LOH was uncommon in B-ALL, and most alterations identified by CMA would be detectable by OGM. Many of these patients also harbored complex structural rearrangements that required multiple conventional assays for full characterization; these could be resolved by OGM in a single analysis. Conclusions: Our findings indicate that although OGM excels at resolving complex structural variants, CMA remains essential for detecting copy-neutral events. Until OGM achieves improved sensitivity for CN-LOH, an integrated approach utilizing conventional cytogenetics, CMA, NGS, and OGM provides the most reliable framework for comprehensive genomic assessment across cancer types.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on healthy immune cells.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on healthy immune cells.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
BTK mutant knock-in cell lines.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
BTK mutant knock-in cell lines.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
PKCβ is accessible and upregulated in dual-refractory CLL.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
PKCβ is accessible and upregulated in dual-refractory CLL.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on BCR Signaling.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on BCR Signaling.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on PKCβ and PKCε in CLL.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on PKCβ and PKCε in CLL.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on Wnt/β-catenin signaling.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 on Wnt/β-catenin signaling.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Clinical characteristics of BTKi resistant CLL patient samples
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Clinical characteristics of BTKi resistant CLL patient samples
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 towards co-culture systems.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Effect of MS-553 towards co-culture systems.